Glycosylation of the immunoglobulin G (IgG)-Fc tail is required for binding to Fc-gamma receptors (FcγRs) and complement-component C1q. A variety of IgG1-glycoforms is detected in human sera. Several groups have found global or antigen-specific skewing of IgG glycosylation, for example in autoimmune diseases, viral infections, and alloimmune reactions. The IgG glycoprofiles seem to correlate with disease outcome. Additionally, IgGglycan composition contributes significantly to Ig-based therapies, as for example IVIg in autoimmune diseases and therapeutic antibodies for cancer treatment. The effect of the different glycan modifications, especially of fucosylation, has been studied before. However, the contribution of the 20 individual IgG glycoforms, in which the combined effect of all 4 modifications, to the IgG function has never been investigated. Here, we combined six glyco-engineering methods to generate all 20 major human IgG1-glycoforms and screened their functional capacity for FcγR and complement activity. Bisection had no effect on FcγR or C1q-binding, and sialylation had no-or little effect on FcγR binding. We confirmed that hypo-fucosylation of IgG1 increased binding to FcγRIIIa and FcγRIIIb by ~17-fold, but in addition we showed that this effect could be further increased to ~40-fold for FcγRIIIa upon simultaneous hypo-fucosylation and hyper-galactosylation, resulting in enhanced NK cellmediated antibody-dependent cellular cytotoxicity. Moreover, elevated galactosylation and sialylation significantly increased (independent of fucosylation) C1q-binding, downstream complement deposition, and cytotoxicity. In conclusion, fucosylation and galactosylation are primary mediators of functional changes in IgG for FcγR-and complement-mediated effector functions, respectively, with galactose having an auxiliary role for FcγRIII-mediated functions. This knowledge could be used not only for glycan profiling of clinically important (antigen-specific) IgG but also to optimize therapeutic antibody applications.
inTrODUcTiOn
The importance of the biological properties of antibodies to specifically engage a target of choice and activate complement and Fc gamma receptors (FcγR) on immune cells (1) is currently more and more recognized in modern medicine. For cancer therapies using tumor targeting antibodies, strong effector functions are preferred (2) . Various strategies have been exploited to generate antibodies that are more effective than wild-type human IgG1 isotype (3) . These include fusions with toxic molecules and incorporations of mutations that enhance affinities to FcγR. Possible drawback of such modifications is the introduction of foreign immunogenic epitopes that can result in anti-drug antibodies that may neutralize the drug. This can be circumvented by using non-immunogenic natural variations, found in all individuals. The prototypic variation of this kind are glyco-engineered IgG1 antibodies without fucose with elevated FcγRIIIa affinities (4, 5) , which have already found its way to therapeutic antibodies on the market (6) . This fucose residue is part of a conserved glycan on asparagine 297 in the Fc domain of immunoglobulin G (IgG). This glycan is important for the quaternary structure of the Fc part, since its removal abrogates binding of FcγR and C1q and hence the antibody's effector functions (7) (8) (9) . In addition to affecting the Fc structure and thereby recognition by these effector molecules, the Fc-glycan also affects binding to FcγRIIIa and FcγRIIIb through a glycan-glycan interaction (10, 11) . This is because of a unique glycan found in human FcγRIIIa and FcγRIIIb at position 162 that interacts directly with the Fc-glycan within the IgG-Fc cavity (11) .
The N297 glycan is a bi-antennary complex glycan composed of a constant part with a core consisting of N-acetylglycosamines and mannoses and can be found in human serum with variable levels of core fucose, bisecting N-acetylglycosamine, galactose, and terminal sialic acids (12) . The N-glycans of total serum/ plasma IgG consists on average of high fucose levels (95%), low bisection (15%), intermediate levels of galactose (45%), and low sialic acid (10%) (12) . The variable assembly of the glycans amounts to at least 20 different glycoforms (a term used here to describe one unique glycan combination) for each IgG subclass being found in serum, with ~8 of them accounting for 90% of the total abundance (12) . The composition of total IgG glycosylation can change upon certain settings, where galactosylation and sialylation increase with pregnancy (12, 13) . Changes in total IgG are also observed in various clinical settings, with a low level of galactosylation and sialylation associated both with increasing age and autoimmune diseases (12) (13) (14) (15) .
We and others have shown that IgG-Fc glycosylation changes of antigen-specific IgG can occur that correlate with disease outcome (16) (17) (18) (19) (20) . This includes both auto-and alloimmune disorders, including fetal neonatal immune thrombocytopenia (FNAIT), immune thrombocytopenia, and hemolytic disease of the fetus and newborn (HDFN) (16-18, 21, 22) . In particular, we have found that immune responses against red blood cell (RBC) and platelets, either transfused or during pregnancy, can be characterized with extremely low fucose (down to 10%), high galactose (up to 80%), and elevated sialylation levels (~35%).
Notably, lowered Fc-fucosylation (17, 21) , but also elevated Fc-galactosylation (18) , seemed to correlate with elevated blood cell destruction, severity of anemia or bleeding for RBCs and platelets, respectively. Whereas the increased pathogenicity associated with lowered fucosylation could be explained by the resulting elevated FcγRIIIa and/or FcγRIIIb activity (17, 23) , the functional reasons-if any-behind the association with elevated galactosylation remained enigmatic.
The effect of Fc-bisection and -sialylation on human FcγR binding, if any, has been studied in even less detail, although binding to the human FcγRIIIa does not seem to be affected by sialylation (24) . Whether these glycan changes influence binding to C1q, and subsequent complement activation, has not been studied in detail (25, 26) . A drawback of all these studies is that the impact of the glycan changes was studied changing only individual end groups, without investigating the possibility that the context of the other glycan changes may have an effect on the antibody effector functions.
The complexity of the glycan-assembly makes investigation into their biological relevance extremely difficult. Previous attempts have generated a handful of defined glycoforms and tested binding to part of the FcγR-repertoire, but a systematic analysis for all possible glycan changes and effector mediators, FcγRs and complement, has never been achieved (24, (26) (27) (28) (29) (30) . This information could provide the insight in working mechanisms of IgG-based treatments and allow meaningful clinical evaluation of the activity of potentially pathological antibodies such as in FNAIT and HDFN. We have, therefore, developed a set of glyco-engineering tools which specifically alter one of the N-glycan end groups (31) and in the present study we combined these tool to create 20 different natural glycoforms to systematically investigate them with regard to FcγR binding, antibody-dependent cellular cytotoxicity (ADCC), complement binding, and activation.
MaTerials anD MeThODs human samples
Peripheral blood from anonymous, healthy volunteers was obtained with informed, written consent in accordance with Dutch regulations. This study was approved by the Sanquin Ethical Advisory Board in accordance with the Declaration of Helsinki.
Heparinized blood samples were used for isolation of peripheral blood mononuclear cells (PBMCs) or RBCs. NK cell isolation was only performed with blood from well-genotyped donors who do not express FcγRIIc (32) to exclude any possible effects of this receptor. Serum was obtained by allowing blood without anticoagulants to coagulate for 1 h at room temperature (RT) and collecting the supernatant after centrifugation at 950 × g for 10 min. Serum of three different volunteers was combined to create a serum pool.
strains and reagents
Escherichia coli strain DH5α was used for recombinant DNA work. Restriction endonucleases, DNA modification enzymes were obtained from Thermo Fisher Scientific (Waltham, MA, USA). Oligonucleotides were obtained from Geneart (Thermo Fisher Scientific) or Integrated DNA Technologies (Coralville, IA, USA).
igg1 expression Vector constructs
Variable (V) genes for anti-human RhD (anti-D clone 19A10) heavy and light chain were sequenced from a single human B cell from a hyper immunized donor (33) . A single-gene vector containing anti-D or anti-TNP IgG1 heavy-and kappa lightchain-encoding sequences were cloned as described previously by Kruijsen et al. (34) into a pEE14.4 (Lonza, Basel, Switzerland) expression vector. For both anti-TNP and anti-D IgG, a single expression vector was generated. In brief, the codon-optimized V gene for both heavy and light chain, including 5′-HindIII and 3′-NheI or 5′-HindIII and 3′-XhoI restriction sites respectively, Kozak sequence, and HAVT20-leader sequence, were designed and ordered from Geneart (Thermo Fisher Scientific). The HindIII-NheI or HindIII-XhoI fragments for the codon-optimized heavy or light chain were ligated into γ or κ constant region flanking 3′-EcoRI restriction site, respectively. The HindIII-EcoRI fragment for the codon-optimized light chain was ligated into pEE14.4 (Lonza), and the HindIII-EcoRI fragment for the heavy chain was ligated into pEE6.4 (Lonza). A single-gene vector encoding IgG1 was subsequently generated by ligation of the BamHI-NotI fragment from pEE6.4 (including a cytomegalovirus promoter), IgG1 heavy chain, and poly (A) into the light-chain-encoding pEE14.4 vector.
igg1 Production and glyco-engineering
IgG1 production in human embryonic kidney (HEK) F cells and purification using protein A affinity chromatography was performed as described previously by Kruijssen et al. (34) Glyco-engineering of IgG1 was optimized as described by Dekkers et al. (31) In short, to decrease either fucosylation or galactosylation, 0.4 mM 2-deoxy-2-fluoro-l-fucose (2FF) (Carbosynth, Berkshire, United Kingdom) or 1 mM 2-deoxy-2-fluoro-d-galactose (2FG) (Carbosynth), respectively, was added to the cell suspension 4 h post transfection. To increase bisecting GlcNAc, 1% pEE6.4 + GNTIII encoding mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase (GNTIII) enzyme was co-transfected with 99% IgG1-κ HC + LC vector. To increase galactose, 1% pEE6.4 + B4GALT1 encoding β-1,4-galactosyltransferase 1 (B4GALT1) enzyme was co-transfected with 99% IgG1 vector and 5 mM d-galactose (Sigma Aldrich, Saint Louis, MO, USA) was added to the cell suspension 1 h before transfection. To increase sialylation, the level of galactosylation must also be elevated as sialic acid is the terminal sugar group with galactose residues as substrate. Thus, 1% pEE6.4 + B4GALT1 and 2.5% pEE14.4 + STGALT encoding β-galactoside alpha-2,6-sialyltransferase 1 (ST6GALT) were both co-transfected 96.5% IgG1 vector and 5 mM d-galactose was added to the cell suspension 1 h before transfection. To further increase sialylation, in vitro sialylation (ivs) was performed on the purified in vivo sialylated IgG created using the previous method. Recombinant human α-2,6-sialyltransferase (Roche, Basel, Switzerland) and cytidine-5′-monophospho-Nacetylneuraminic acid (CMP-NANA) (Roche) were incubated at 37°C for 24 h with purified IgG1 with already in vivo enhanced galactose and sialic acid (as described above), after incubation samples were re-purified with protein A, as described previously (31, 34) .
Mass spectrometry analysis
Immunoglobulin G-Fc glycan composition of produced IgG1 was determined by mass spectrometry as described previously by Dekkers et al. (31) Trypsin-digested glycopeptide samples were analyzed by nanoLC-ESI-QTOF-MS. The separation was performed on an RSLCnano Ultimate 3000 system (Thermofisher, Breda, the Netherlands) with a gradient pump, loading pump and an autosampler. 250 nl of sample was injected and washed on a Dionex Acclaim PepMap100 C18 trap column (5 mm × 300 µm i.d.; Thermofisher) for 1 min with 0.1% TFA at a flow rate of 25 µl/ min. The sample was then separated on an Ascentis Express C18 nanoLC analytic column (50 mm × 75 µm i.d.; 2.7-µm fused core particles; Supelco, Bellefonte, PA) with a flow rate of 0.9 µl/min using linear gradient as described in Ref (30) . The resulting coelution of the different glycoforms of the IgG1-Fc glycosylation site warrants fair comparison by ensuring identical ionization conditions for the various glycopeptide species. The LC was coupled to the MS detector via a CaptiveSpray source with a NanoBooster (Bruker Daltonics, Bremen, Germany). The latter enriched the N2 flow (3 l/min) with CH3CN (pressure 0.2 bar), resulting in increased sensitivity. The samples were ionized in positive ion mode at 1,100 V. The Maxis Impact quadrupole-TOF-MS (micrOTOF-Q, Bruker Daltonics) was used as detector. MS1 spectra were collected at a frequency of 1 Hz with a scan range of m/z 550-1,800. The mass spectrometric data were calibrated internally in DataAnalysis 4.0 (Bruker Daltonics) using a list of known IgG glycopeptide masses. MSConvert (Proteowizard 3.0) (35) was used to convert the data files to mzXML format, and an in-house alignment tool (36) was used to align the retention times of the data files. The highest intensity of selected peaks (within an m/z window of ±0.2 and within a time window of ±15 s surrounding the retention time) was extracted using the in-house developed 3D Max Xtractor software tool. If above a signal:background ratio of 3, the background-subtracted area of the first three isotopic peaks of each glycopeptide in both 2+, 3+, and 4+ charge state were summed, and this summed value was then divided by the total summed value of all IgG1 glycopeptides to arrive at a percentage for each glycopeptide. From these percentages, we calculated several derived traits using the following formulas: fucosylation (H3N3F1 + H4N3F1 + H5N3 F1 + H6N3F1 + G0F + G1F + G2F + H6N4F1 + G0FN + G1F N + G2FN + H6N5F1 + H4N3F1S1 + H5N3F1S1 + H6N3F1 S1 + G1FS + G2FS + H6N4F1S1 + G2FS2 + G1FNS + G2FNS + H6N5F1S1 + G2FNS2), bisection (H6N4F1 + G0FN + G1FN + G2FN + H6N5F1 + H6N4F1S1 + G1FNS + G2FNS + H6N5 F1S1 + G2FNS2 + H6N4 + G0N + G1N + G2N + H6N5 + H 6N4S1 + G1NS + G2NS + H6N5S1 + G2NS2), galactosylation [(H4N3F1 + H5N3F1 + G1F + H6N4F1 + G1FN + H6N5F1 + H4N3F1S1 + H5N3F1S1 + H6N3F1S1 + G1FS + H6N4F1S 1 + G1FNS + H6N5F1S1 + H4N3 + H5N3 + H6N3 + G1 + H6N4 + G1N + H6N5 + H4N3S1 + H5N3S1 + H6N3S1 + G1 S + H6N4S1 + G1NS + H6N5S1) * 0.5 + G2F + G2FN + G2 
, hybrid-types (H5N3F1 + H6N3F1 + H6N4F1 + H6N5F1 + H5N3F1S1 + H6N3F1S1 + H6N4F1S 1 + H6N5F1S1 + H5N3 + H6N3 + H6N4 + H6N5 + H5N3S1 + H6N3S1 + H6N4S1 + H6N5S1), and high-mannose (H5N2 + H6N2 + H7N2 + H8N2 + H9N2). For some of the minor hybridtype glycans, it could not be determined conclusively whether a galactose or a bisecting N-acetylglucosamine was present, so an educated guess was made based on structural knowledge (for instance, since the hybrid glycan H6N4F1 is elevated in GNTIIIco-transfected HEK cell-derived IgG samples, it is likely to be a bisected species rather than triantennary). Cr, PerkinElmer, Waltham, MA, USA) at 10 9 cells/ml. An amount of 10 5 erythrocytes were incubated with NK cells for 2 h at 37°C in a 2:1 ratio in Iscove's modified dulbecco's medium (IMDM, Gibco, Thermo Fisher Scientific) supplemented with 10% fetal calf serum (FCS, Bodinco, Alkmaar, The Netherlands) and anti-D IgG1-glycoforms at a total volume of 100 µl. To determine 100% lysis, 2.5% saponine (Fluka, Sigma Aldrich) was added to RBC in control wells and spontaneous lysis (sp) was determined by incubation of RBC without NK cells. Supernatants were collected and released 51 Cr was quantified in a Packard Cobra II Auto-Gamma Counter Model D5005 (PerkinElmer). The data represent the mean and SEM of at least two combined independent experiments; *, **, ***, and **** denote a statistical significance of p ≤ 0.05, p ≤ 0.01, p ≤ 0.001, and p ≤ 0.0001, respectively, as tested by one-way ANOVA against unmodified IgG1, using Dunnett's multiple comparisons test. U: unmodified glycoform. To coat, maxisorp plates (Thermo Scientific, Nunc flat-bottom 96-well plate) were incubated o/n at RT with 20 µg/ml HSA-TNP in PBS. The plates were washed 5× with PBS + 0.1% tween-20 (Sigma-Aldrich) (wash buffer) using an ELISA washer (Biotek, 405 LSRS). All following washing steps were done similarly. The IgG samples were diluted in 100 µl PBS/plx [PBS + 0.1% poloxamer (Sigma-Aldrich, poloxamer 407)] per well and incubated for 1.5 h at RT. The plates were washed and incubated with 100 µl 1:35 serum pool in VB +/+ /plx {veronalbuffer [3 mM Barbital (Sigma-Aldrich), 1.8 mM Sodium-Barbital (Sigma Aldrich), 0.146 M NaCl (Fagron, Capelle aan den Ijssel, The Netherlands), pH 7.4] + 10 mM CaCl2 (Merck) + 2 mM MgCl2 (Merck) + 0.1% poloxamer} for 1 h at RT. When C1q was blocked, 10 min prior to addition of serum to the ELISA plate, anti-C1q-85 blocking antibody (42) was added to the VB +/+ /plx + 1:35 serum solution in a 1:2 molar ratio of C1q:anti-C1q-85 with final concentration of 8.57 µg/ml anti-C1q-85. The plates were washed and 100 µl with either 2 µg/ml biotinylated anti-C1q-2 (42), 0.5 µg/ml biotinylated anti-C4-10 (43), 0.6 µg/ml biotinylated anti-C3-19 (44), or 1 µg/ml HRP labeled anti-human IgG (Sanquin, Peliclass) in PBS/plx was added to respectively detect C1q, C4b, C3b, or IgG deposition and incubated for 1 h at RT. The plates were washed, C1q, C4b, and C3 plates were incubated with 100 µl 0.2 µg/ml strep-poly HRP (Sanquin, Peliclass) (C1q) or 0.25 µg/ ml strep-HRP (Sigma-Aldrich) (C4b and C3b) in PBS/plx for 1 h at RT. The plates were washed and developed for 5-10 min using 100 µl TMB mix composed of 0.11 M NaAc (pH 5.5) (Merck), 0.1 mg/ml 3,3′,5,5′-Tetramethylbenzidine (Merck) and 0.003% H2O2 (Merck) and the reaction was stopped with the addition of 100 µl 2 M H2SO4 (Merck). The optical density (OD) was measured at A450 nm using a plate reader (Biotek, Synergy 2, Winooski, VT, USA).
The results were analyzed with a parallel line assay in Microsoft Office Excel (45) . We assessed the potency of the glycoforms relative to a standard, an independently titrated unmodified IgG1; these values were expressed as percentages relative to the unmodified glycoform. ). This amount of RBC was taken to ensure the 100% absorbance between 1.8 and 2.2 delta (Δ) A412-A690 nm. The plates were incubated for 90 min at 37°C while shaking at 150 rpm (Orbital incubator S150, 16 mm shaking diameter). After incubation, 1.25% w/v saponine was supplemented to the 100% control wells, 100 µl VBG −/− was added to all wells and the plates were centrifuged for 2 min at 350 × g. Subsequently, 150 µl of supernatant was transferred into a separate plate and OD was measured at Δ A412-A690 nm using a plate reader. The percentage of lysed cells was calculated as follows:
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OD sample-OD spontaneous OD 100%-OD spontaneous % ( )= × 100 . In GraphPad Prism, we calculated the half maximal effective concentration (EC50) for each replicate of the different glycoforms using a non-linear fit for normalized response with a variable slope and combined these to an average EC50.
statistical analysis
Statistical analyses were performed using GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla, CA, USA). The level of significance was set at p < 0.05 using twotailed tests.
resUlTs recapitulation of all 20 Major Different glycoforms Found in human Plasma
Human IgG1, produced in HEK cells, shows complex-type bi-antennary glycans similar to IgG from normal human plasma ( Figure 1A) (31, 46) . More specifically, without any modification ("Unmodified, " box labeled "U" in the x-axis legend, Figures 1B-E) HEK-derived IgG1 N-glycans feature high fucosylation, low bisection, intermediate-level galactosylation, and low sialylation (Figures 1B-E) . We previously developed six glyco-engineering tools which can be implemented upon protein production, as we recently described (31) . These were aimed to decrease fucosylation, increase bisection, decrease or increase galactosylation, or increase sialylation. In the present study, these tools were combined and used in all possible combinations during the transient transfection in HEK cells, which resulted in the anticipated glycosylation changes and allowed us to produce the 20 major glycoforms present in human serum. Only minor unanticipated effects (Figures 1B-E) , were observed. A slight increase in galactosylation upon overexpression of beta 1,4-N-acetylglucosaminyltransferase III (GntIII) to increase bisection (e.g., 28 to 36% upon GntIII expression)-but this was only observed in samples with low starting-levels of galactosylation (Figures 1C,D) . Some of the tools caused a minor increase (<21%) in high-mannose or hybrid glycan species ( Figure S1 and Table S1 in Supplementary Material) (31) . Using the glyco-engineering tools the most extreme levels were reached for fucose and galactose (Figures 1B,D) , bisection was increased up to 60%, and sialylation never reached over half of what was possible by the underlying galactose (~40%). The level of sialylation was, therefore, further increased using in vitro sialylation as described before (up to ~70%) ( Figure 1E ; Table 1 ) (31, 47, 48) . All in all, this resulted in 20 combinations and markedly different glycoforms. All 20 glycoforms were produced as two panels of IgG1, specific for the RhD (anti-D) antigen or 2,4,6-trinitrophenyl hapten (anti-TNP) (34), with both panels showing highly comparable glycosylation patterns depending of the glyco-engineering tools applied ( Table 1; Table S1 in Supplementary Material). To avoid any possible confounding effects of Fab glycosylation on IgG function, we used anti-D and anti-TNP with variable domains sequences devoid of N-linked glycosylation sites.
Binding of igg glycome to human Fcγr
We next used the IBIS MX96 biosensor system, as described in Dekkers et al. (39) , capable of analyzing the binding of up to 48 different receptor ligand interactions in parallel by SPR, to probe the affinity of all IgG1-glycoforms to all human FcγRs and their allotypes affecting IgG binding (Table S2 in Supplementary Material) (49) . The antibodies used for these experiments (anti-D) showed no signs of dimers or multimers ( Figure S2 in Supplementary Material). The binding affinities of unmodified IgG1 to the different receptors resembled those reported earlier (Table 2) (49). We considered significant changes in the apparent KD of more than twofold from unmodified IgG to be potentially meaningful changes and within the scope of the SPR method, using a simplified 1:1 Langmuir model that does not fully represent the actual interaction which is more complicated (39) . No significant effects of glycan changes above twofold were seen on the binding to FcγRIa, FcγRIIa (neither the H131-or the R131-allotype), or FcγRIIb/c (Figures 2A-D) . However, marked changes were seen for all FcγRIII-isoforms. Reduction of fucose resulted in enhanced binding to all FcγRIII species by approximately 10-to 20-fold depending on the type-and allotype (Figures 2E-H) , as reported (4, 5) . Importantly, addition of galactose consistently enhanced binding of hypo-fucosylated IgG1 for all FcγRIIIa allotypes, doubling the effect of hypofucosylation alone (Figures 2E,F) . This effect was also seen for allotypes of FcγRIIIb, but less strong and only for IgG1 that was bisected in addition to hypo-fucosylated (Figures 2G,H) . Further sialylation of low-fucosylated galactosylated IgG1 had little additional effect on the binding to FcγRIII, except for hypo-fucosylated and bisected IgG1 for both allotypes of FcγRIIIa and FcγRIIIb NA2, where sialylation cause a significant decrease in binding. Taken together, glycan changes 
, and (h) FcγRIIIb NA2. x-Axis legend describes the percentage of each derived glycan trait indicated and by grayscale, from light to dark. The data represent the mean and SEM of at least two combined independent experiments; *, **, ***, and **** (above each column as tested against unmodified, or as indicated, for FcγRIIIs comparing each set of five glycoforms defined by the vertical dotted lines, based on fucose and bisection levels) denote a statistical significance of p ≤ 0.05, p ≤ 0.01, p ≤ 0.001, and p ≤ 0.0001, respectively, as tested by one-way ANOVA using Tukey's multiple comparisons test. U: unmodified glycoform. Material). Only hypo-fucosylated IgG1 induced ADCC in variable degrees depending on the glycosylation (Figures 3A,B) . The observed level of ADCC were in line with the binding results obtained by SPR for each of the FcγRIIIa allotypes (Figure 3C) , confirming the essential role of both hypo-fucosylation and elevated galactosylation for increased FcγRIIIa-binding and effector functions. Again, sialic acid had a minor but significant negative effect, especially for the bisected, hypo-fucosylated, and galactosylated IgG1 (Figures 3A,B) . Remarkably, the wellknown allotypic differences in affinity were confirmed by our SPR expe riments, but not by the functional NK cell-mediated ADCC.
galactosylation and sialylation Direct complement Binding and activation glycoform also showed a direct relationship with the efficacy of C1q binding, and EC50 (Figures 5C,D) . In conclusion, the degree of galactosylation, but also sialylation of the IgG1-Fc N-glycan directly steers the antibody's efficacy to stimulate complement deposition and CDC.
DiscUssiOn
We have previously created an orthogonal set of glyco-engineering tools (31) which we now combined to create 20 glycovariants of human IgG1, representing natural variants found in human plasma IgG, including extreme glycoforms found for examples in patients with FNAIT and HDFN (17, 18, 21, 22) . These variants were investigated for their functional capacity to engage and activate FcγR and complement.
Of the FcγRs, we only observed an effect of glycosylation on binding to the FcγRIII-family of receptors, both FcγRIIIa and FcγRIIIb and their allotypes, which confirms and expands recent studies using a limited set of glycovariants presented here (24, 30) . Increased FcγRIII binding seems to be a general phenomenon for all IgG subclasses upon afucosylation (50, 51) . The positive binding effects were primarily caused by the lack of fucose, which was further strengthened by additional galactose. A similar effect has been observed for neutralizing anti-HIV antibody 2G12 produced in modified plant cells which showed better FcγRIIIa binding and antibody-dependent (NK) cell-mediated viral inhibition (52) .
The enhanced binding of galactosylated and afucosylated IgG was slightly weakened by addition of sialic acid, but only if a bisecting GlcNAc was present. A similar negative effect of sialylation has previously been observed for mouse FcγR by Ravetch and colleagues (53) . Importantly, we showed that the enhanced FcγRIII-binding effects are directly translated into increased FcγR-mediated cellular functions. We tested this using NK cell-mediated ADCC, as NK cells are the only cell type that only express FcγRIIIa. Curiously, we observed no ADCC at all for fucosylated IgG, even at high concentrations of IgG1. Thus, ADCC activity was only observed with afucosylated IgG1. Although somewhat surprising, this phenomenon has been observed previously for anti-Rhesus-mediated ADCC (54), but also for Rituximab-mediated B cell killing (27) . This suggests that the enhanced affinity afucosylation of IgG has on FcγRIIIa binding is required to cross a signaling threshold of FcγRIIIa on NK cells required for killing.
The second surprise was that no significant difference was observed between ADCC-capacity of NK cells from donors homozygous for one of the two FcγRIIIa-V/F158 allotypes, of which the V158 allele is known to have higher affinity for IgG (also confirmed here to be ~2-5×) (49) . In vitro, this has been found result in stronger functional efficacy for the V158-variant (55) (56) (57) . In vivo, conflicting reports have showed that individuals homozygous either the V158 or the F158 allotype show stronger cellular clearance (58) (59) (60) (61) . It should be noted that most of these studies were performed before the knowledge of FcγRIII gene being influenced by copy number variation (61) . We also now know that NK cells can also express FcγRIIc or FcγRIIb in some individuals. Both these variations affect the functionality of this receptor (32, 62, 63) . In this study, we eliminated both these variables by selecting donors with two copies of FcγRIIIa and without FcγRIIc-ORF, possibly explaining these discrepancies, and perhaps suggesting that the twofold to fivefold difference in affinity of IgG1 allotype is not enough to cause functional differences.
Importantly, the observed changes in FcγRIIIa-binding due to glycosylation reliably translated into functional NK cellmediated ADCC lysis of RBC. For FcγRIIIa and FcγRIIIb it was known that absence of IgG-Fc core-fucosylation increases the affinity of interaction due to a glycan-glycan interaction between the Fc glycan and the N162-glycan uniquely found in the FcγRIII family (11) . Our approach to combine this with multiple end glycan editing shows an additional layer of complexity exerted by the galactose and sialic acid. The reasons for this added effect of galactose is unknown but may very well be related to the subtle effects on quaternary structure of the Fc-domain (64, 65) but may also be related to differential interaction of the Fc-glycan with the N162-glycan found in FcγRIII (11) .
The possible effect of the Fc-glycans on complement activity, has until now remained enigmatic. It has been proposed for a long time that agalactosylated IgG activates complement more efficiently through the lectin pathway (MBL) (25) . To our knowledge these results have never been confirmed. On the contrary, we saw enhanced complement activity of all glycovariants with elevated galactose, and no evidence of MBL being activated by any of our glycoforms. These results confirm recent work also suggesting galactosylation of IgG1 to positively influence C1q binding and CDC (26, 66) . In addition, our results clearly rule out fucosylation or bisection having an effect on complement activation, and we now show that sialylation increases the C1q-binding of galactosylated IgG. This effect of sialylation was observed on all different glycan backbones (e.g., with or without fucose, with or without bisection) which is highly suggestive that this is no artifactual finding. This is in contrast with the previously mentioned study showing that additional sialylation decreases C1q binding (26) . Activation of complement is dependent on spatial arrangement of the IgG on the cell surface (67) which is likely to differ considerably between each monoclonal antibody and target, and may possibly explain the discrepancies found between our two studies. This view is supported by our observations that sialylation had limited if any effect on IgG-mediated CDC using RBC as targets, while binding to C1q of anti-TNP antibodies was enhanced by sialylated IgG on solid surfaces.
Low galactosylation level in total IgG generally correlates with disease severity of several autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis (13, 14) . While this may seem at odds with our observations at first glance, with high galactosylated IgG having elevated complement and FcγR activities, both notions are in agreement if the balance between total-and antigen-specific glycosylation is taken into account. In this way, low potential for FcγR-and C1q binding for total IgG (e.g., low galactosylation), creates a pro-inflammatory environment in which clinical manifestations can take hold as this lowers the threshold for pathogenic antibodies. Antigen-specific IgG can also potentially have different glycosylation features than total IgG as we have shown before (17, 18, 21, 22) , and if these are more pro-inflammatory than that of total IgG, this can theoretically lead to enhanced immune activation and clinical symptoms. The knowledge obtained in the current research provides a roadmap to decipher the meaning of glycan profiles in these diseases settings.
In summary, we show here that a set of glyco-engineering techniques we recently developed (31) can be combined to quickly generate any desired IgG glycoforms to test the effect on functional capacity. Using two sets of monoclonal antibodies we generated the most extreme 20 different glycoforms possible, and examined their effect on binding to FcγR and complement, as well as their functional capacity to trigger cytotoxicity. These revealed first that the normal glycosylation changes seen in human IgG1 do not affect any other FcγR than FcγRIIIa and FcγRIIIb. Second, hypo-fucosylation and galactosylation increase binding to both human FcγRIII-variants, with a minor negative effect of sialic acid and bisecting GlcNAc. In addition, galactosylation is the primary glycan adduct that enhances C1q-binding and all downstream complement activities, including CDC. This is summarized in Figure 6 . Collectively, this indicates that afucosylated and hyper-galactosylated IgG1 antibodies have both improved ADCC and complement-mediated activities, including complement opsonization and CDC. These properties can now be systematically implemented in new therapeutic antibodies for enhanced effector functions. Even as important, this also allows us to decipher the clinical potency of antibodies in immune responses that have tendency to have altered fucosylation and/ or galactosylation (17, 18, 21, 22) .
